

## Anti-ADAM9 Antibody (Imgc936)

### Introduction

Anti-ADAM9 (Imgc936) is a humanized antibody targeting ADAM metalloproteinase domain 9 (ADAM9). It is a drug candidate for the treatment of multiple cancers, including non-small cell lung cancer, pancreatic cancer, gastric cancer, breast cancer, ovarian cancer, and colorectal cancer.

### Product parameters

Alternative Names	AEX6003
Target Accession	Q13443
Target	ADAM9
CAS number	2642078-62-2
Molecular Weight	147.62 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	The endocytosis ratio Imgc936 by Human ADAM9 HT29 increased with the increase of antibody concentration, and the Internalization Rate (%) reached 50% at antibody concentration of 1 nM.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## Note

1. This product is for scientific research use only.



### **APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

